buy

Nektar Therapeutics buy BTIG Research

Nektar Therapeutics

Start price

€0.58

/ 50%

Target price

19.09.26

Performance (%)

Price

Summary

This prediction has just been started. It does not have a price yet.. This prediction currently runs until 19.09.26. The prediction end date can be changed by BTIG_Research at any time.

Nektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.

Feedback

Performance without dividends (%)

Name	1w
Nektar Therapeutics
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by BTIG_Research for this prediction

In the thread Discuss Nektar Therapeutics

Prediction Buy

Perf. (%) -

Target price 84.910

Change

Ends at

Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $100.00 price target on the stock.

Ratings data for NKTR provided by MarketBeat

BTIG Research